Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. Its proprietary product pipeline focuses on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis; and PUR1800, kinase inhibitor for patients with obstructive lung diseases, including asthma and chronic obstructive pulmonary disease (COPD). The company is also involved in developing PUR0200, a reformulation of an existing long-acting antimuscarinic agent that has completed Phase Ib clinical development, which blocks the effects of acetylcholine on muscarinic receptors to reverse airway obstruction in COPD patients. It has a license agreement with RespiVert Ltd. to develop kinase inhibitor for access to a portfolio of novel drug candidates; and a partnership agreement with Vectura Group plc to develop its drug candidate. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PULM
Previous Symbol
CUSIPN/A
Phone781-357-2333
Debt
Debt-to-Equity RatioN/A
Current Ratio2.38
Quick Ratio2.38
Price-To-Earnings
Trailing P/E Ratio-0.41
Forward P/E Ratio-0.57
P/E GrowthN/A
Sales & Book Value
Annual Sales$340,000.00
Price / Sales53.83
Cash FlowN/A
Price / CashN/A
Book Value$0.48 per share
Price / Book0.81
Profitability
EPS (Most Recent Fiscal Year)($0.93)
Net Income$-18,050,000.00
Net MarginsN/A
Return on Equity-172.66%
Return on Assets-117.18%
Miscellaneous
Employees24
Outstanding Shares46,930,000
Market Cap$18.87 million
OptionableOptionable
Pulmatrix (NASDAQ:PULM) Frequently Asked Questions
What is Pulmatrix's stock symbol?
Pulmatrix trades on the NASDAQ under the ticker symbol "PULM."
How were Pulmatrix's earnings last quarter?
Pulmatrix Inc (NASDAQ:PULM) released its quarterly earnings data on Friday, August, 3rd. The biotechnology company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.04. View Pulmatrix's Earnings History.
When is Pulmatrix's next earnings date?
What price target have analysts set for PULM?
1 equities research analysts have issued 12-month target prices for Pulmatrix's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Pulmatrix's stock price to reach $3.00 in the next year. This suggests a possible upside of 689.5% from the stock's current price. View Analyst Price Targets for Pulmatrix.
What is the consensus analysts' recommendation for Pulmatrix?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pulmatrix in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Pulmatrix.
Has Pulmatrix been receiving favorable news coverage?
News stories about PULM stock have been trending somewhat positive this week, InfoTrie reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pulmatrix earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Pulmatrix's key competitors?
Some companies that are related to Pulmatrix include Arcturus Therapeutics (ARCT), Medicure (MCUJF), BIOLINERX Ltd/S (BLRX), Oramed Pharmaceuticals (ORMP), Elite Pharmaceuticals (ELTP), Forward Pharma A/S (FWP), Immune Design (IMDZ), Vaccinex (VCNX), Nemus Bioscience (NMUS), Novan (NOVN), Alpine Immune Sciences (ALPN), Bellerophon Therapeutics (BLPH), Vistagen Therapeutics (VTGN), Sophiris Bio (SPHS) and Oncomed Pharmaceuticals (OMED).
Who are Pulmatrix's key executives?
Pulmatrix's management team includes the folowing people:
- Dr. Robert W. Clarke, CEO, Pres & Director (Age 49)
- Mr. Teofilo David Raad, Chief Bus. Officer (Age 48)
- Dr. James M. Roach, Chief Medical Officer (Age 58)
- Dr. Robert S. Langer Jr., Founder & Member of Scientific Advisory Board (Age 69)
- Prof. David A. Edwards, Founder & Member of Scientific Advisory Board (Age 57)
How do I buy shares of Pulmatrix?
Shares of PULM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pulmatrix's stock price today?
One share of PULM stock can currently be purchased for approximately $0.38.
How big of a company is Pulmatrix?
Pulmatrix has a market capitalization of $18.87 million and generates $340,000.00 in revenue each year. The biotechnology company earns $-18,050,000.00 in net income (profit) each year or ($0.93) on an earnings per share basis. Pulmatrix employs 24 workers across the globe.
What is Pulmatrix's official website?
How can I contact Pulmatrix?
Pulmatrix's mailing address is 99 HAYDEN AVENUE SUITE 390, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-357-2333 or via email at [email protected]
MarketBeat Community Rating for Pulmatrix (NASDAQ PULM)
MarketBeat's community ratings are surveys of what our community members think about Pulmatrix and other stocks. Vote "Outperform" if you believe PULM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PULM will underperform the S&P 500 over the long term. You may vote once every thirty days.
